BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Allist Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Allist Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04853342-1983@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT04853342)
DESCRIPTION:Furmonertinib\, phase 3.\nStudy: To Assess the Efficacy and Saf
 ety of Furmonertinib Versus Placebo\, in Patients With Epidermal Growth Fa
 ctor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinom
 a\, Following Complete Tumour Resection With or Without Adjuvant Chemother
 apy\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04853342
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008288-2045@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glecirasib: Phase 2 readout est. (NCT06008288)
DESCRIPTION:Glecirasib\, phase 2.\nStudy: A Phase II Study Evaluating JAB-2
 1822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid 
 Tumors Harboring the KRAS p.G12C Mutation.\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gle
 cirasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06008288
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288205-2045@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid 
 Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0528820
 5
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05276726-2045@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05276726)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and ST
 K11 Co-mutation and Wild-type KEAP1\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05276726
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956001-1983@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06956001)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Versus Platinum Based Chemotherapy as First-line Treatment fo
 r NSCLC With EGFR PACC or EGFR l861q Mutation\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fur
 monertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06956001
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010419-1983@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07010419)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo f
 or Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Unco
 mmon Epidermal Growth Factor Receptor (EGFR) Mutations\, Following Complet
 e Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）\nE
 stimated primary completion: 31 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07010419
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185997-1983@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07185997)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Invest
 igator's Choice of EGFR Inhibitor as First-Line Treatment in Participants 
 Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C
 -Helix Compressing (PACC) Uncommon Mutations\nEstimated primary completion
 : February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furm
 onertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07185997
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970639-1983@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06970639)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy V
 ersus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR)
  Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NS
 CLC) and Brain Metastases\nEstimated primary completion: March 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06970639
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2045@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Glecirasib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Glecirasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JAB-
 21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment 
 of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstimate
 d primary completion: 30 September 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
